Compare JAZZ & H Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JAZZ | H |
|---|---|---|
| Founded | 2003 | 1957 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.6B | 17.8B |
| IPO Year | 2007 | 2009 |
| Metric | JAZZ | H |
|---|---|---|
| Price | $254.86 | $189.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 15 |
| Target Price | ★ $217.57 | $179.53 |
| AVG Volume (30 Days) | ★ 789.8K | 696.7K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.38% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.43 | 0.40 |
| Revenue | $1,618,693,000.00 | ★ $4,685,000,000.00 |
| Revenue This Year | $6.22 | $110.63 |
| Revenue Next Year | $7.68 | $7.01 |
| P/E Ratio | ★ $54.96 | $473.69 |
| Revenue Growth | N/A | ★ 5.78 |
| 52 Week Low | $105.00 | $133.51 |
| 52 Week High | $250.49 | $206.86 |
| Indicator | JAZZ | H |
|---|---|---|
| Relative Strength Index (RSI) | 65.44 | 49.67 |
| Support Level | $222.49 | $182.02 |
| Resistance Level | N/A | $206.86 |
| Average True Range (ATR) | 7.53 | 4.96 |
| MACD | 0.49 | -0.81 |
| Stochastic Oscillator | 99.98 | 60.21 |
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
Hyatt is an operator of owned (2% of total rooms) and managed and franchised (98%) properties across about 35 upscale luxury brands, which include vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. Regional exposure, as a percentage of total rooms, is 45% for the US, 31% for the rest of the world, and 24% for Asia-Pacific.